The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Amgen; Faraday Pharmaceuticals; Ipsen; Merus; Novartis; Pancreatic Cancer Action Network; Regeneron; Valar Labs; Varian Medical Systems
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - Rayzebio
 
Stephen Garrett Marcus
No Relationships to Disclose
 
Warren S. Brenner
No Relationships to Disclose
 
Marc Isamu Uemura
No Relationships to Disclose
 
Ki Y. Chung
Research Funding - epizyme (Inst); MedImmune (Inst)
 
Donald A. Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Nathan Bahary
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Incyte